XTL Biopharmaceuticals Ltd. (XTLB.TA)
ILA 5.2
(-7.14%)
ILA 5.2
(-7.14%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -707 Thousand | -901 Thousand | -1.04 Million | -850 Thousand | -908 Thousand | -816 Thousand |
| Net Income | -1.78 Million | -1.34 Million | 435 Thousand | -782 Thousand | -1.34 Million | 2.98 Million |
| Depreciation & Amortization | - | 1000.00 | 1000.00 | 1000.00 | - | - |
| Deferred income taxes | - | 487 Thousand | -1.46 Million | -132 Thousand | - | - |
| Stock-based compensation | 3000.00 | 14 Thousand | 37 Thousand | 51 Thousand | 5000.00 | 24 Thousand |
| Change in working capital | 64 Thousand | -19 Thousand | -54 Thousand | 45 Thousand | -50 Thousand | -8000.00 |
| Other non-cash items | -41 Thousand | -36 Thousand | -8000.00 | -33 Thousand | 484 Thousand | -3.81 Million |
| Investing Cash Flow | 41 Thousand | 36 Thousand | 8000.00 | 32 Thousand | 2.11 Million | 778 Thousand |
| Investments in PPE | - | - | - | -1000.00 | -2000.00 | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | -6.3 Million |
| Sales/Maturities of investments | - | - | - | - | 2.02 Million | 7 Million |
| Other Investing Activities | 41.00 | 36 Thousand | 8000.00 | 33 Thousand | 93 Thousand | 74 Thousand |
| Financing Cash Flow | - | - | 385 Thousand | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | 385.00 | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 19 Thousand | -44 Thousand | -23 Thousand | 22 Thousand | -21 Thousand | -47 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 45.00 | 25 Thousand | -31 Thousand | 23 Thousand | -29 Thousand | 39 Thousand |
| Cash at beginning of period | 2.09 Million | 2.96 Million | 3.63 Million | 4.45 Million | 3.25 Million | 3.28 Million |
| Cash at end of period | 1.4 Million | 2.09 Million | 2.96 Million | 3.63 Million | 4.45 Million | 3.25 Million |
| Capital Expenditure | - | - | - | -1000.00 | -2000.00 | - |
| Effect of forex changes on cash | -27 Thousand | -10 Thousand | -6000.00 | -6000.00 | -3000.00 | 4000.00 |
| Net cash flow / Change in cash | -693 Thousand | -875 Thousand | -662 Thousand | -824 Thousand | 1.2 Million | -34 Thousand |
| Free Cash Flow | -707 Thousand | -901 Thousand | -1.04 Million | -851 Thousand | -910 Thousand | -816 Thousand |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 485 Thousand | -1.78 Million | -284 Thousand | -215 Thousand | -364 Thousand | -919 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 3000.00 | 3000.00 | - | - | - |
| Change in working capital | - | 64 Thousand | - | - | - | - |
| Other non-cash items | -485 Thousand | -41 Thousand | 281 Thousand | 215 Thousand | 364 Thousand | 919 Thousand |
| Investing Cash Flow | - | 41 Thousand | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 41.00 | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | 19 Thousand | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | 45.00 | - | - | - | - |
| Cash at beginning of period | - | 2.09 Million | - | 5.89 Million | 6.85 Million | 7.38 Million |
| Cash at end of period | - | 1.4 Million | - | 5.54 Million | 5.89 Million | 6.85 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | -27 Thousand | - | - | - | - |
| Net cash flow / Change in cash | - | -693 Thousand | - | -349.9 Thousand | -958.93 Thousand | -533.04 Thousand |
| Free Cash Flow | - | -707 Thousand | - | - | - | - |
INV
KMK
0165
DRXGY
AMSU
DIS